CTMX - CIK 0001501989
CytomX Therapeutics, Inc. (CTMX) reported net income of -$17.37M for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Net Income | Change |
|---|---|---|
| FY 2025 | -$17.37M | -154.5% |
| FY 2024 | $31.87M | +5700.9% |
| FY 2023 | -$569.00K | +99.4% |
| FY 2022 | -$99.32M | +14.3% |
| FY 2021 | -$115.87M | -78.8% |
| FY 2020 | -$64.82M | +51.2% |
| FY 2019 | -$132.82M | -57.0% |
| FY 2018 | -$84.60M | -96.3% |
| FY 2017 |
CytomX Therapeutics, Inc. (CTMX) reported net income of -$17.37M for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2013 and fiscal 2025, CytomX Therapeutics, Inc.'s net income declined from -$15.14M to -$17.37M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| -$43.10M |
| +26.8% |
| FY 2016 | -$58.90M | -66.5% |
| FY 2015 | -$35.37M | -16.7% |
| FY 2014 | -$30.31M | -100.2% |
| FY 2013 | -$15.14M | - |